Breaking News Instant updates and real-time market news.

GSK

GlaxoSmithKline

$36.76

(0.00%)

, PFE

Pfizer

$36.27

-0.06 (-0.17%)

22:34
03/21/18
03/21
22:34
03/21/18
22:34

GlaxoSmithKline in lead to buy Pfizer consumer unit, FT says

With Reckitt Benckiser (RBGLY) already having confirmed it is out of the bidding for Pfizer's (PFE) Consumer Healthcare unit, stating that an acquisition for the whole business "did not fit" its acquisition criteria and an acquisition of part of the business "was not possible," GlaxoSmithKline (GSK) is in pole position to buy the owner of the Advil and Centrum brands, according to Financial Times. Pfizer has said it was considering a sale or spinoff of the business, or it could still decide to keep the division, the report added. Reference Link

GSK

GlaxoSmithKline

$36.76

(0.00%)

PFE

Pfizer

$36.27

-0.06 (-0.17%)

RBGLY

Reckitt Benckiser

$16.14

0.18 (1.13%)

  • 25

    Mar

  • 04

    Apr

  • 23

    Apr

GSK GlaxoSmithKline
$36.76

(0.00%)

01/22/18
WBLR
01/22/18
NO CHANGE
WBLR
Outperform
Dynavax has sold off 30% since Heplisav approval, says William Blair
Dynavax (DVAX) shares have pulled back about 30% since the U.S. approval of Heplisav, the first and only two-dose hepatitis B vaccine that has demonstrated "superiority in efficacy and comparability" in safety to the standard of care, GlaxoSmithKline's (GSK) Engerix-B, William Blair analyst Katherine Xu tells investors in a research note. The analyst attributes the selloff to Dynavax electing to launch Heplisav on its own and the Street having insufficient confidence in the launch. She believes Heplisav has peak U.S. sales prospects of $600M and "provides a valuation floor." Xu also sees catalysts on the oncology side of the business. She maintains an Outperform rating on Dynavax with a $40 per share fair value estimate.
01/22/18
WELS
01/22/18
NO CHANGE
WELS
Underperform
Teva can't afford more pipeline setbacks, says Wells Fargo
After Teva (TEVA) reported that its Phase 3 registration study evaluating subcutaneously administered reslizumab in a pre-filled syringe did not meet its primary endpoint, Wells Fargo analyst David Maris said he believes this puts Teva at a disadvantage versus peers AstraZeneca (AZN) and GlaxoSmithKline (GSK) at a time when Teva cannot afford more pipeline setbacks. Subcutaneous reslizumab was not a major focus, but the news is still "another disappointment," said Maris, who keeps an Underperform rating on Teva shares.
02/08/18
MSCO
02/08/18
NO CHANGE
MSCO
Equal Weight
Gilead Biktarvy approval, Glaxo patent suit not surprising, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said investors expected Gilead (GILD) to receive FDA approval for its once-daily single tablet regimen to treat HIV-1 infection, now named Biktarvy, so he would expect limited impact on the stock from the news. He also said GlaxoSmithKline's (GSK) filing of patent infringement litigation alleging that Biktarvy infringes on ViiV's dolutegravir is not a surprise given prior comments by GSK and he would expect this to work through the courts. Harrison, who added that Biktarvy's clean label is a positive, keeps an Equal Weight rating on Gilead shares.
02/22/18
LEER
02/22/18
NO CHANGE
LEER
Rapid adoption of Gilead Biktarvy to challenge GlaxoSmithKline outlook, says Leerink
Leerink analyst Seamus Fernandez notes he has recently completed a MEDACorp survey of U.S. HIV treatment specialists and has found "impressively positive" sentiment about Gilead's (GILD) Biktarvy which seems likely to put sustained pressure on GlaxoSmithKline's (GSK) leading integrase inhibitor Tivicay, as well as cannibalizing Gilead's other combination and component products.
PFE Pfizer
$36.27

-0.06 (-0.17%)

12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.
01/29/18
RHCO
01/29/18
NO CHANGE
Target $40
RHCO
Hold
Pfizer price target raised to $40 from $33 at SunTrust
SunTrust analyst John Boris raised his price target on Pfizer to $40 and kept his Hold rating ahead of this week's earnings. The analyst attributes the price outlook revision to the positive impact of the tax changes, but notes that "transformative large-scale M&A" is needed to bring about return to "robust" long-term growth.
02/07/18
HCWC
02/07/18
NO CHANGE
Target $31
HCWC
Buy
Achaogen price target raised to $31 from $25 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Achaogen (AKAO) to $31 after the FDA classified the outcome of its Q4 reinspection of Pfizer's (PFE) McPherson, Kansas facility as Voluntary Action Indicated. The news provides a clear regulatory path for approval of plazomicin out of the McPherson facility, Arce tells investors in a research note. He views the outcome as an "important risk-reducing development" that removes an overhang on Achaogen shares. The analyst keeps a Buy rating on the name.
02/16/18
SBSH
02/16/18
NO CHANGE
Target $78
SBSH
Buy
Three developments make Pfizer buying Bristol-Myers more likely, says Citi
Citi analyst Andrew Baum raised his price target for Bristol-Myers Squibb (BMY) to $78 from $72 saying three developments over the last week have increased the probability of a Pfizer (PFE) takeover to near 65% from 50%. Bristol closed yesterday up $3.64, or 5.6%, to $68.98. First, Bristol's revenue potential in non-small cell lung cancer is partly de-risked through Checkmate-227 tumor mutation burden data, Baum tells investors in a research note. Second, the NKTR-214 development collaboration and equity stake in Nektar Therapeutics (NKTR) could materially increase Bristol's Opdivo market share, the analyst adds. And third, he believes Pfizer's immuno-oncology efforts "are looking increasingly suspect." Bristol-Myers is likely Pfizer's last chance to have a meaningful position in the $50B-plus per annum immuno-oncology market, Baum contends. He reiterates a Buy rating on Bristol shares.
RBGLY Reckitt Benckiser
$16.14

0.18 (1.13%)

07/06/17
JEFF
07/06/17
DOWNGRADE
JEFF
Hold
Reckitt Benckiser downgraded to Hold from Buy at Jefferies
Jefferies analyst Martin Deboo downgraded Reckitt Benckiser to Hold saying the recent share rally no longer leaves sufficient upside for a Buy rating. The analyst raised his price target to 8,400p from 7,750p.

TODAY'S FREE FLY STORIES

LYV

Live Nation

$48.15

-0.53 (-1.09%)

17:46
08/17/18
08/17
17:46
08/17/18
17:46
Hot Stocks
Live Nation CFO discloses sale of 40K shares of common stock »

Live Nation CFO Elizabeth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$72.63

0.21 (0.29%)

, XLU

Utilities SPDR

$54.50

0.25 (0.46%)

17:40
08/17/18
08/17
17:40
08/17/18
17:40
General news
Week ending ETF Scorecard: Consumer Staples outperforms, Energy skids »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$72.63

0.21 (0.29%)

XLU

Utilities SPDR

$54.50

0.25 (0.46%)

IYR

DJ US Real Estate Index Fund

$83.16

0.765 (0.93%)

XLP

Consumer Staples Sector SPDR

$55.02

0.39 (0.71%)

XLY

Consumer Discretionary Sector SPDR

$112.51

0.11 (0.10%)

XLB

S&P Select Materials SPDR

$58.41

0.41 (0.71%)

XLF

Financial Select Sector

$28.16

0.055 (0.20%)

XLV

Health Care Select Sector SPDR

$91.12

0.33 (0.36%)

XLK

Technology Select Sector SPDR

$73.17

0.14 (0.19%)

XLI

Industrial Select Sector SPDR

$76.26

0.47 (0.62%)

GLD

SPDR Gold Trust

$112.12

1.01 (0.91%)

SLV

iShares Silver Trust

$13.93

0.16 (1.16%)

USO

United States Oil Fund

$13.70

0.065 (0.48%)

UNG

United States Natural Gas Fund

$24.18

0.295 (1.24%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$86.03

0.08 (0.09%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.97

0.11 (0.09%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.99

0.16 (0.13%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.49

0.04 (0.04%)

SHY

iShares 1-3 Year Treasury Bond

$83.28

0.03 (0.04%)

IWD

iShares Russell 1000 Value

$126.16

0.6 (0.48%)

IWF

iShares Russell 1000 Growth

$150.80

0.27 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$112.12

1.01 (0.91%)

17:33
08/17/18
08/17
17:33
08/17/18
17:33
Hot Stocks
SPDR Gold Trust holdings fall to 772.24MT from 773.41MT »

This is the 5th…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDOT

Green Dot

$85.04

0.37 (0.44%)

17:30
08/17/18
08/17
17:30
08/17/18
17:30
Hot Stocks
Green Dot exec Dent sells 7,754 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SMSI

Smith Micro

$2.49

-0.01 (-0.40%)

17:17
08/17/18
08/17
17:17
08/17/18
17:17
Syndicate
Breaking Syndicate news story on Smith Micro »

Smith Micro files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDRA

ENDRA Life Sciences

$2.70

0.2 (8.00%)

17:14
08/17/18
08/17
17:14
08/17/18
17:14
Syndicate
Breaking Syndicate news story on ENDRA Life Sciences »

ENDRA Life Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$346.44

0.55 (0.16%)

17:10
08/17/18
08/17
17:10
08/17/18
17:10
Hot Stocks
Boeing awarded $152.5M U.S. Navy contract »

Boeing is awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$346.44

0.55 (0.16%)

17:09
08/17/18
08/17
17:09
08/17/18
17:09
Hot Stocks
Boeing awarded $217M Defense Department contract »

The Boeing Co has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$210.37

0.56 (0.27%)

17:08
08/17/18
08/17
17:08
08/17/18
17:08
Hot Stocks
L3 Technologies awarded $240M Defense Department contract »

L-3 Communications was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSGX

Histogenics

$2.65

-0.05 (-1.85%)

17:06
08/17/18
08/17
17:06
08/17/18
17:06
Syndicate
Breaking Syndicate news story on Histogenics »

Histogenics files $75M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLD

Prologis

$67.45

1.79 (2.73%)

, DCT

DCT Industrial

$68.77

1.805 (2.70%)

16:58
08/17/18
08/17
16:58
08/17/18
16:58
Conference/Events
DCT Industrial to host special shareholder meeting »

Special Shareholder…

PLD

Prologis

$67.45

1.79 (2.73%)

DCT

DCT Industrial

$68.77

1.805 (2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLK

Westlake Chemical

$95.61

-1.33 (-1.37%)

16:56
08/17/18
08/17
16:56
08/17/18
16:56
Hot Stocks
Westlake Chemical expands share repurchase program by $150M »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 11

    Sep

SM

SM Energy

$27.38

0.17 (0.62%)

16:55
08/17/18
08/17
16:55
08/17/18
16:55
Recommendations
SM Energy analyst commentary at MUFG »

SM Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

PENN

Penn National

$33.04

0.86 (2.67%)

16:51
08/17/18
08/17
16:51
08/17/18
16:51
Hot Stocks
Penn National CEO acquires 100,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$173.78

-0.98 (-0.56%)

16:49
08/17/18
08/17
16:49
08/17/18
16:49
Periodicals
U.S. wants Facebook to help wiretap Messenger for criminal probe, Reuters says »

The U.S. government is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 06

    Sep

  • 18

    Sep

WLK

Westlake Chemical

$95.61

-1.33 (-1.37%)

16:46
08/17/18
08/17
16:46
08/17/18
16:46
Hot Stocks
Westlake Chemical raises quarterly dividend 19% to 25c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 11

    Sep

EAST

Eastside Distilling

$7.40

-0.01 (-0.13%)

16:45
08/17/18
08/17
16:45
08/17/18
16:45
Syndicate
Breaking Syndicate news story on Eastside Distilling »

Eastside Distilling files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOV

Spark Networks

$12.80

-0.095 (-0.74%)

16:44
08/17/18
08/17
16:44
08/17/18
16:44
Syndicate
Spark Networks files to sell 515,416 ordinary shares for holders »

Including 222 ordinary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AHPA

Avista Healthcare Public Acquisition Corp.

$10.12

(0.00%)

16:42
08/17/18
08/17
16:42
08/17/18
16:42
Hot Stocks
Avista Healthcare Public Acquisition Corp., Organogenesis announce combination »

Avista Healthcare Public…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCF

TCF Financial

$25.84

0.17 (0.66%)

16:41
08/17/18
08/17
16:41
08/17/18
16:41
Hot Stocks
TCF Financial COO sells 77,725 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGF.A

Lionsgate

$22.95

-0.11 (-0.48%)

16:38
08/17/18
08/17
16:38
08/17/18
16:38
Recommendations
Lionsgate analyst commentary at Barrington »

Lionsgate price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

16:35
08/17/18
08/17
16:35
08/17/18
16:35
General news
Breaking General news story  »

Moody's cuts Turkey…

MSL

MidSouth Bancorp

$14.90

0.1 (0.68%)

16:32
08/17/18
08/17
16:32
08/17/18
16:32
Hot Stocks
MidSouth Bancorp says 'will carefully review' letter sent by Jacobs Asset Mgt. »

MidSouth Bancorp issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EME

EMCOR

$77.96

1.005 (1.31%)

16:31
08/17/18
08/17
16:31
08/17/18
16:31
Hot Stocks
Emcor CEO sells 23,434 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
08/17/18
08/17
16:30
08/17/18
16:30
Options
Preliminary option volume of 22.3M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.